1. Home
  2. DNTH vs UVE Comparison

DNTH vs UVE Comparison

Compare DNTH & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNTH
  • UVE
  • Stock Information
  • Founded
  • DNTH 2015
  • UVE 1990
  • Country
  • DNTH United States
  • UVE United States
  • Employees
  • DNTH N/A
  • UVE N/A
  • Industry
  • DNTH Biotechnology: Pharmaceutical Preparations
  • UVE Property-Casualty Insurers
  • Sector
  • DNTH Health Care
  • UVE Finance
  • Exchange
  • DNTH Nasdaq
  • UVE Nasdaq
  • Market Cap
  • DNTH 780.2M
  • UVE 666.1M
  • IPO Year
  • DNTH N/A
  • UVE 1992
  • Fundamental
  • Price
  • DNTH $26.50
  • UVE $24.58
  • Analyst Decision
  • DNTH Strong Buy
  • UVE
  • Analyst Count
  • DNTH 8
  • UVE 0
  • Target Price
  • DNTH $54.00
  • UVE N/A
  • AVG Volume (30 Days)
  • DNTH 374.5K
  • UVE 153.4K
  • Earning Date
  • DNTH 11-06-2025
  • UVE 10-23-2025
  • Dividend Yield
  • DNTH N/A
  • UVE 3.13%
  • EPS Growth
  • DNTH N/A
  • UVE N/A
  • EPS
  • DNTH N/A
  • UVE 2.28
  • Revenue
  • DNTH $4,854,000.00
  • UVE $1,567,371,000.00
  • Revenue This Year
  • DNTH N/A
  • UVE $1.87
  • Revenue Next Year
  • DNTH N/A
  • UVE N/A
  • P/E Ratio
  • DNTH N/A
  • UVE $10.79
  • Revenue Growth
  • DNTH 17.87
  • UVE 5.64
  • 52 Week Low
  • DNTH $13.37
  • UVE $16.50
  • 52 Week High
  • DNTH $32.27
  • UVE $28.49
  • Technical
  • Relative Strength Index (RSI)
  • DNTH 70.68
  • UVE 51.55
  • Support Level
  • DNTH $22.81
  • UVE $24.09
  • Resistance Level
  • DNTH $24.81
  • UVE $24.65
  • Average True Range (ATR)
  • DNTH 1.57
  • UVE 0.54
  • MACD
  • DNTH 0.22
  • UVE 0.12
  • Stochastic Oscillator
  • DNTH 91.57
  • UVE 48.28

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

About UVE UNIVERSAL INSURANCE HOLDINGS INC

Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.

Share on Social Networks: